WOBURN, Mass., Sept. 25 /PRNewswire/ -- CutisPharma, Inc. has been selected by Medicine Shoppe International, Inc. (MSI) as its preferred vendor for unit-of-use compounding kits. CutisPharma's FIRST(TM)-Unit-of-Use Prescription Compounding Kits will allow more Medicine Shoppe(R) and Medicap Pharmacy(R) franchisees the ability to offer compounding service to customers or, for pharmacies already providing the service, to increase the efficiency of their compounding offerings. Compounding services, the customization of medication according to a doctor's prescription that meets an individual patient's medical needs, is currently available in approximately 60 percent of Medicine Shoppe and Medicap Pharmacy stores.
FIRST(TM)-Unit-of-Use Prescription Compounding Kits are designed to offer pharmacists the ability to benefit physicians, pharmacists and patients. The kits enable the pharmacist or technician to compound based on the receipt of a valid prescription for an individual patient.
"Our FIRST(TM)-Unit-of-Use Prescription Compounding Kits are user-friendly, save compounding time by over 70 percent, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction and eliminating the need for an extra trip to the pharmacy for the customer," said Dr. Indu Muni, Chairman & CEO of CutisPharma. "A single NDC number assigned for the entire kit simplifies the third party reimbursement process, reduces audit-related adjustments, and FIRST(TM) Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>."
"CutisPharma has a great understanding of the industry and the business needs of our franchisees," said Keith Cook, R.Ph., vice president of pharmacy solutions, Medicine Shoppe International, Inc. "The FIRST(TM)-Unit-of-Use Prescription Compounding Kits will offer our franchisees and pharmacists everything they need to easily compound specific prescriptions, especially if they do not already maintain a compounding practice. The increase in compounding efficiency and customer satisfaction will aid franchisees in growing this piece of niche business."
CutisPharma currently has nine proprietary prescription compounding kits on the market: five strengths of progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and one Magic Mouthwash kit. Several more compounding kits are in the planning stages.
The FDA estimates that each year in the United States about 30 million retail and hospital outpatient prescriptions are prepared through compounding. About 1 percent of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.
About Medicine Shoppe International, Inc.
Medicine Shoppe International, Inc. http://www.medicineshoppe.com, a Cardinal Health Company, is one of the largest franchisors of independent community pharmacies in the U.S. In 2003, Medicine Shoppe International acquired Medicap Pharmacies Incorporated http://www.medicap.com, which franchises independent community pharmacies in the U.S. under the trade name Medicap Pharmacy(R). Medicine Shoppe(R) and Medicap Pharmacy(R) locations are distinguished for their commitment to providing expert, personalized health care. In 2007, Medicine Shoppe pharmacies were awarded top honors for "Highest Customer Satisfaction among Chain Drug Store Pharmacies" by J.D. Power and Associates. There are more than 900 domestic Medicine Shoppe pharmacies and Medicap Pharmacy locations and more than 400 Medicine Shoppe pharmacies in six other countries.
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on developing and commercializing value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts, initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 8 million currently compounded prescriptions, by offering FIRST(TM) Unit-of-Use Prescription Compounding Kits. A U.S. patent has been issued to the Company and additional patents are pending.
|SOURCE CutisPharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved